Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

The populations of wealthy western nations are getting older and sicker, while emerging countries are demanding better ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

UnitedHealth Group (UNH 1.05%) and Eli Lilly (LLY +1.45%) are two of the largest and most powerful healthcare companies in ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

"Scandalous unveiling on the 'Presidential Walk of Fame' sends shockwaves through Washington. You won't believe what Trump's ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.